Additionally, ORIC-533 (9) has emergedas a highlypotent small-molecule inhibitor, surpassing the potency of AB680,and is currently in phase I trials as the first oral CD73 inhibitorfor the treatment of relapsed or refractory multiple myeloma.37 As a new type of nucleotide, ORIC-533 has beenreported to exhibit high metabolic stability with a half-life of 2.98h in mice, and it features slow dissociation from CD73.39,40 These properties enable it to effectively restore cytokine secretionof CD8+ T cells and inhibit tumor growth when it is administeredorally as a single agent.41 Here, CD8A is linked to neoplasm.